STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.

MLA

Woelfel, Simon, et al. “STAR SIGN Study: Evaluation of COVID‐19 Vaccine Efficacy against the SARS‐CoV‐2 Variants BQ.1.1 and XBB.1.5 in Patients with Inflammatory Bowel Disease.” Alimentary Pharmacology & Therapeutics, vol. 58, no. 7, Oct. 2023, pp. 678–91. EBSCOhost, https://doi.org/10.1111/apt.17661.

APA

Woelfel, S., Dütschler, J., König, M., Dulovic, A., Graf, N., Junker, D., Oikonomou, V., Krieger, C., Truniger, S., Franke, A., Eckhold, A., Forsch, K., Koller, S., Wyss, J., Krupka, N., Oberholzer, M., Frei, N., Geissler, N., Schaub, P., & Albrich, W. C. (2023). STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 58(7), 678–691. https://doi.org/10.1111/apt.17661

Chicago

Woelfel, Simon, Joel Dütschler, Marius König, Alex Dulovic, Nicole Graf, Daniel Junker, Vasileios Oikonomou, et al. 2023. “STAR SIGN Study: Evaluation of COVID‐19 Vaccine Efficacy against the SARS‐CoV‐2 Variants BQ.1.1 and XBB.1.5 in Patients with Inflammatory Bowel Disease.” Alimentary Pharmacology & Therapeutics 58 (7): 678–91. doi:10.1111/apt.17661.